Kerala Daily

DelveInsight Business Research LLP

(United States, Nevada, Las Vegas),DelveInsight’s “Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder- Pipeline Insight, 2023” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in the CDKL5 Deficiency Disorder pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space

Key Takeaways from the Cyclin-dependent Kinase-like 5 Deficiency Disorder Pipeline Report

• Over 5+ companies and 5+ pipeline drugs in Cyclin-dependent Kinase-like 5 Deficiency Disorder are in various stages of development, and their anticipated acceptance in the Cyclin-dependent Kinase-like 5 Deficiency Disorder market would significantly increase market revenue. 

• Leading Cyclin-dependent Kinase-like 5 Deficiency Disorder companies developing novel drug candidates to improve the Cyclin-dependent Kinase-like 5 Deficiency Disorder treatment landscape include UCB S.A, Ultragenyx Pharmaceutical, Amicus Therapeutics, Ovid Therapeutics, REGENXBIO, and others.

• Promising Cyclin-dependent Kinase-like 5 Deficiency Disorder pipeline therapies in various stages of development include Fenfluramine and others.

Cyclin-dependent Kinase-like 5 Deficiency Disorder Overview

Cyclin-dependent Kinas Like 5 deficiency disorder is a rare developmental encephalopathy (DE) caused by pathogenic variants in the gene cyclin-dependent kinase-like 5 (CDKL5). It is a rare X-linked genetic disorder first identified in 2004. The most common symptoms include early-onset, difficult-to-control seizures and neurodevelopmental impairment that affects cognitive, motor, speech, and visual function. The Cyclin-dependent kinase-like 5 Deficiency disorder gene is responsible for creating a protein necessary for normal brain development and function.

Cyclin-dependent Kinase-like 5 Deficiency Disorder Pipeline Analysis: Drug Profile

Fenfluramine: UCB S.A.

Fenfluramine is an investigational serotonin-releasing agent that has been shown to stimulate multiple 5-HT receptor sub-types through the release of serotonin. Fenfluramine may reduce seizures by acting as an agonist at specific serotonin receptors in the brain, including the 5-HT1D, 5-HT2A, and 5-HT2C receptors, and also by acting on the sigma-1 receptor. Currently, the drug is in the Phase III stage of Clinical trial evaluation for the treatment of CDKL5 Deficiency Disorder.

Discover more about the emerging Cyclin-dependent Kinase-like 5 Deficiency Disorder drugs @ Cyclin-dependent Kinase-like 5 Deficiency Disorder Treatment Drugs

Cyclin-dependent Kinase-like 5 Deficiency Disorder Pipeline Therapies and Key Companies

• Fenfluramine: UCB S.A.

And many others

Cyclin-dependent Kinase-like 5 Deficiency Disorder Pipeline Therapeutics Assessment

Phases

DelveInsight’s Report covers around 5+ products under different phases of clinical development like

• Late-stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I) along with the details of

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

Route of Administration

Cyclin-dependent Kinase-like 5 Deficiency Disorder pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular

• Intraocular

• Intrathecal

• Intravenous

• Ophthalmic

• Oral

• Parenteral

• Subcutaneous

• Topical

• Transdermal

 Molecule Type

Products have been categorized under various Molecule types such as

• Oligonucleotide

• Peptide

• Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination, and Mono/Combination.

Scope of the Cyclin-dependent Kinase-like 5 Deficiency Disorder   Pipeline Report 

• Coverage: Global 

• Key Cyclin-dependent Kinase-like 5 Deficiency Disorder Companies: UCB S.A, Ultragenyx Pharmaceutical, Amicus Therapeutics, Ovid Therapeutics, REGENXBIO, and others

• Key Cyclin-dependent Kinase-like 5 Deficiency Disorder Pipeline Therapies: Fenfluramine and others

Find out more about the Cyclin-dependent Kinase-like 5 Deficiency Disorder treatment options in development @ Cyclin-dependent Kinase-like 5 Deficiency Disorder Clinical Trials

Table of Contents

1. Cyclin-dependent Kinase-like 5 Deficiency Disorder Introduction

2. Cyclin-dependent Kinase-like 5 Deficiency Disorder Executive Summary

3. Cyclin-dependent Kinase-like 5 Deficiency Disorder Overview

4. Cyclin-dependent Kinase-like 5 Deficiency Disorder Pipeline Therapeutics

5. Cyclin-dependent Kinase-like 5 Deficiency Disorder Late-Stage Products (Phase III)

6. Cyclin-dependent Kinase-like 5 Deficiency DisorderMid-Stage Products (Phase  II)

7. Cyclin-dependent Kinase-like 5 Deficiency Disorder Early Stage Products (Phase  I/II)

8. Cyclin-dependent Kinase-like 5 Deficiency Disorder Preclinical Stage Products

9.  Cyclin-dependent Kinase-like 5 Deficiency Disorder Discovery Stage Products

10. Cyclin-dependent Kinase-like 5 Deficiency Disorder Therapeutic Assessment

11. Cyclin-dependent Kinase-like 5 Deficiency Disorder Inactive Products

12. Cyclin-dependent Kinase-like 5 Deficiency Disorder Collaborations Assessment- Licensing / Partnering / Funding

13. Cyclin-dependent Kinase-like 5 Deficiency Disorder Unmet Needs

14. Cyclin-dependent Kinase-like 5 Deficiency Disorder Market Drivers and Barriers

15. Appendix

16. About DelveInsight

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Adya Kaul
Email: Send Email
Phone: 919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services